Humulin N

Humulin N is a prescription insulin product that contains the active ingredient insulin human. It is supplied in a neutral (N) formulation for subcutaneous or intramuscular injection and is marketed in the European Union. The preparation provides a basal, long‑acting insulin profile and is used to help manage blood glucose in patients with diabetes. Strength and specific vial or pen format follow standard concentrations for human insulin.

Humulin N is indicated for the long‑term control of blood glucose in adults and children with diabetes.

- Basal insulin therapy for type 1 diabetes mellitus when combined with rapid‑acting insulin. - Basal insulin therapy for type 2 diabetes mellitus as part of a multi‑dose regimen. - Adjunct to dietary management and exercise in patients requiring a steady insulin background. - Use in insulin‑deficient states where a prolonged glucose‑lowering effect is desired. - Replacement therapy for patients with inadequate endogenous insulin production.

Like all insulin products, Humulin N may be associated with adverse reactions that vary in frequency and severity.

Common: - Hypoglycemia (low blood glucose) – the most frequently reported event. - Injection site reactions such as redness, swelling, or itching. - Weight gain associated with improved glycemic control. - Lipodystrophy (localized fat accumulation or loss) at injection sites. - Nausea or abdominal discomfort. - Headache.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Hypersensitivity with eosinophilia or fever. - Insulin edema causing peripheral swelling. - Serum electrolyte disturbances such as hypokalemia.

When prescribing or using Humulin N, clinicians and patients should consider several safety precautions to minimize risks.

- Monitor blood glucose regularly to detect and treat hypoglycemia promptly. - Adjust dose during periods of illness, fasting, or changes in physical activity. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Avoid use in individuals with known hypersensitivity to insulin human or any formulation component. - Pregnancy and lactation status should be evaluated; insulin requirements may change. - Educate patients on proper injection technique to reduce lipodystrophy. - Review concomitant medications that can mask hypoglycemia symptoms.

Humulin N can interact with other medicines, affecting glucose control or insulin activity.

Avoid: - Concurrent use of sulfonylureas or meglitinides, which also lower blood glucose. - Combination with high‑dose beta‑blockers that may mask hypoglycemia signs. - Co‑administration with systemic corticosteroids that can increase insulin resistance.

Use with caution: - Concurrent thiazide diuretics, which may raise blood glucose levels. - Concurrent ACE inhibitors or ARBs, which can potentiate insulin’s glucose‑lowering effect. - Concurrent oral contraceptives or hormone replacement therapy, which may alter insulin requirements. - Concurrent alcohol intake, which can cause unpredictable glucose fluctuations.